GlassScriptPhysician profile
Ann H Calland
NPI 1114924107
$7,280.96
in general payments reported to CMS, 2019-2025
33 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $1,051 · 2021: $1,021 · 2022: $951 · 2023: $1,141 · 2024: $1,284 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,485.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,390.90 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,389.35 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $788.86 | 2019-2025 | |
| Novo Nordisk INC | $779.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $577.35 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $398.93 | 2019-2023 | |
| Abbott Laboratories | $178.81 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $178.31 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $161.90 | 2019-2024 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $152.57 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.47 | 2019-2023 | Trulance, Xifaxan |
| Exact Sciences Corporation | $135.07 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $134.44 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Xeris Pharmaceuticals, INC. | $91.97 | 2024-2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $90.71 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $83.38 | 2023-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $64.29 | 2019-2022 | |
| Astellas Pharma US INC | $57.70 | 2019-2025 | Veozah |
| Corium, LLC | $56.46 | 2023-2024 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $55.85 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.22 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $50.30 | 2019-2021 | |
| Allergan, INC. | $49.19 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.47 | 2021-2023 | Jardiance |
| Phathom Pharmaceuticals, INC. | $25.17 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $24.83 | 2020-2021 | |
| Dexcom, INC. | $23.54 | 2023 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $20.83 | 2025 | Symbravo |
| Lundbeck LLC | $20.71 | 2025 | Vyepti |
| Shield Therapeutics INC | $15.18 | 2025 | |
| Currax Pharmaceuticals LLC | $12.42 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.26 | 2022 | |
| Shire North American Group INC | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Calland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.